Page personnelle

Nicolas LEPAREUR, CR CLCC


Skills

– Design and synthesis of various ligands and complexes;
– Radiolabelling of small molecules and nanoparticles, Automation of syntheses;
– Preparation of clinical lots, syringes preparation and dispensation;
– In vitro and in vivo experiments;
– Project management (public grants and industrial contracts);
– Interns and Ph.D. students’ management.

Research topics and scientific objectives

– Development of new radiolabelled compounds for therapy and imaging.

Education and main positions held

– Since 2006: Radiopharmaceutical Scientist – Comprehensive Cancer Centre Eugène Marquis (Rennes)
– 2004: Junior Research Associate – Ecole Nationale Supérieure de Chimie de Rennes/Centre Eugène Marquis
– 2003: Dottoratto di Ricerca in Scienze Chimiche – Università degli Studi di Ferrara (Italy)
– 2003: PhD in Chemistry – University Rennes 1 (France)
– 2000: Engineer in Chemistry and Chemical Engineering – Ecole Nationale Supérieure de Chimie de Rennes
– 2000: MSc in Chemistry – University Rennes 1/ENSCR

Current projects

– 188Re-SSS/Lipiodol for selective internal radiotherapy of HCC: phase 1 clinical trial, technology transfer to Russia and India – industrial partnership (IRE)
– 90Y-radiolabelled Lipiodol: development of a novel radiotracer – industrial contract
– 188Re-lipidic nanocapsules: preclinical development in HCC and endometrial adenocarcinoma, transfer to clinic in glioblastoma (ANR and CGO funding) – collaboration with INSERM U1066 (Angers)
– 188Re-labelled somatostatin analog for HCC metastases targeting: Ligue funding – collaboration with Toulouse University
– 99mTc-labelled polymeric nanoparticles – collaboration with ENSCR and Subatech (Nantes)

Selected publications

Development of biocompatible and functional polymeric nanoparticles for site-specific delivery of radionuclides.
 N. Lepareur, L. Leal e Costa, M. Bocqué, C. Blondelle, C. Ruello, M. Desjulets, N. Noiret, S. Cammas-Marion
Front. Med., 2015, 2:63. doi: 10.3389/fmed.2015.00063


188Re-SSS/Lipiodol: development of a potential treatment for HCC from bench to bedside.
 N. Lepareur, V. Ardisson, N. Noiret, E. Garin
Int. J. Mol. Imaging, 2012, Article ID 278306, 9 pages, doi:10.1155/2012/278306


Composition for treating liver cancer in humans based on rhenium-188 and method for preparing such a composition.
 N. Noiret, E. Garin, N. Lepareur, V. Ardisson
Patent Application WO 2011101436


Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with 188Re-lipid nanocapsules.
 C. Vanpouille-Box, F. Lacoeuille, C. Belloche, N. Lepareur, L. Lemaire, J.-J. Lejeune, J.-P. Benoit, P. Menei, O. Couturier, E. Garcion, F. Hindré
Biomaterials, 2011, 32, 6781-6790


Development and biodistribution of 188Re-SSS lipiodol following injection into the hepatic artery of healthy pigs.
 E. Garin, N. Noiret, C.-H. Malbert, N. Lepareur, A. Roucoux, S. Caulet-Maugendre, A. Moisan, J. Lecloirec, J.-Y. Herry, P. Bourguet
Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 542-546


HAL Publications

Les commentaires sont clos.